{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.5"},{"groupId":"OG001","value":"72.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"description":"The 1-year PFS rate was defined as the percentage of participants surviving 1 year after randomization without disease progression or death.","groups":[{"description":"Velcade 1.3 mg/m2 was administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 were taken orally.","id":"OG000","title":"Part 2: VMP (Velcade+Melphalan+Prednisone)"},{"description":"Siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP. VMP: Velcade 1.3 mg/m2 was administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 were taken orally.","id":"OG001","title":"Part 2: VMP (Velcade+Melphalan+Prednisone) + Siltuximab"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat (ITT) population: all randomized participants","reportingStatus":"POSTED","timeFrame":"1 year","title":"1-year Progression-Free Survival (PFS) Rate","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}